<DOC>
	<DOCNO>NCT01374165</DOCNO>
	<brief_summary>Prolong propose test safety , tolerability pharmacokinetics SANGUINATE™ sickle cell disease ( SCD ) patient . Prolong 's preclinical study show SANGUINATE™ safe number different animal model toxicology study . In Phase I trial , Prolong test whether also safe tolerable sickle cell patient . The study conduct 15 adult ( &gt; 18 year ) patient .</brief_summary>
	<brief_title>Safety Pharmacokinetics SANGUINATE™ Sickle Cell Disease ( SCD ) Patients</brief_title>
	<detailed_description>This Phase I trial test two dos SANGUINATE™ adult subject suffer chronic sickle cell disease ( SCD ) . A total fifteen ( 15 ) patient assign low high dose cohort SANGUINATE™ . The first 8 subject receive study agent initial low dose 160 mg/kg SANGUINATE™ . Upon completion low dose cohort , safety variable review Principal Investigator , Study Manager , Sponsor ( designee ) order determine progression towards administration high dose cohort 320 mg/kg SANGUINATE™ . 7 subject enrol high dose cohort . Subjects enrol next high dose cohort dose precede dose group deem safe tolerable . Sample Size : A total 15 patient enrol study ( 8 patient low dose cohort , 7 patient high dose cohort ) . In cohort additional participant would enrol prior safety review result previously enrol participant . Dose Mode Administration : SANGUINATE™ PEGylated bovine hemoglobin ( PEG-Hb ) CO form formulate saline ( PEG-Hb-CO ) . The study drug supply 500 mL bag red color sterile solution ready infusion without dilution mixing . SANGUINATE™ infuse intravenously 2 hour . The concentration product 40 mg/ml . Dosing Schedule : The study include two cohort SANGUINATE™ : The low dose cohort receive 160 mg/kg ; The high dose cohort receive 320 mg/kg . Laboratory clinical assessment participant conduct 24 hour ( +/-1 hour ) start study drug administration . An additional participant would enrol prior safety review result previously enrol participant cohort . Upon completion low dose cohort , safety data review Principal Investigator , Study Manager , Sponsor ( designee ) order determine progression towards administration high dose cohort . Assessments : Safety : The following assessment use evaluate safety SANGUINATE™ administration : - adverse event , serious adverse event - laboratory abnormality high toxicity grade A complete CBC platelet perform screen Day 1 ( upon admission clinical unit prior dose ) , post-dose Days 2 , 3 7 . Blood biochemistry test ( include amylase lipase ) , urinalysis microscopic , perform screening Day 0 ( admission ) , Day 1 ( 6 hour post-infusion ) Days 2 , 3 , 4 , 5 , 7 . Troponin I test ( cardiac assessment ) perform discretion PI upon Day 0 ( admission ) , Day 1 ( baseline , 1 , 3 , 6 hour post-infusion ) Days 2 , 3 , 4 , 5 , 7 . Renal injury assess via urinalysis follow serum chemistry component : urea nitrogen , creatinine , creatinine clearance , potassium , chloride , magnesium calcium . Pulse oximetry arterial blood pressure capture Day 1 baseline , every 5 minute infusion , every 15 minute post-infusion 1 hour , every 15 minute thereafter value return baseline . Continuous 3-lead ECG monitoring perform Day 1 15-min prior infusion 1 hour post-infusion afterward parameter return baseline . 12-lead ECG capture screening , Day 1 ( baseline , immediately post-infusion , 10 hour post-infusion ) , Days 2 , 3 7 . Pharmacokinetics : Descriptive statistic ( N , mean , standard deviation , standard error mean , CV , median , minimum , maximum ) use summarize single dose serum SANGUINATE™ concentration data plan sampling time point treatment cohort . Serial blood sample pharmacokinetic analysis collect pre-dose 0.5 , 1 , 1.5 , 2 , 4 , 6 , 8 , 12 , 24 , 36 , 48 , 72 96 hour start infusion . Plasma analyze Prolong concentration SANGUINATE™ . The blood volume require perform blood test pharmacokinetic analysis 5 ml collection time point . Safety analysis perform adverse event abnormal laboratory value assess accord standard grading system provide . All safety analysis perform intent treat population ( patient receive least one dose least one post baseline safety measurement ) . All data report individual patient listing . Non-compartmental pharmacokinetic method use determine pharmacokinetic parameter estimate SANGUINATE™ , include Cmax , Cmin , tmax , AUC 0- &gt; , AUC 0 - &gt; , 1/2 , CL/F , accumulation index steady state . Precautionary Statement : Subjects must inform may receive either low high dose drug SANGUINATE™ SANGUINATE™ proven efficacious safe human . Possible Risks Side Effects : There potential side effect result physical intravenous administration drug sting , discomfort , bleeding , bruising , erythema edema skin site penetration infusion . Bovine hemoglobin potential induce allergic response , although SANGUINATE™ design specifically reduce likelihood symptom . Symptoms may encounter SANGUINATE™-allergic subject include : - Local skin reaction wheal flare response local vascular reaction phlebitis . - Wheezy breathlessness 1-7 hour administration - An increase asthmatic symptom . - Rarely , anaphylactic response may encounter . The bovine hemoglobin use manufacture SANGUINATE™ purify inactivate virus remove foreign protein . There know risk BSE/TSE .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Eligibility Criteria : Sickle cell patient enrol select base : Inclusion : 1 . Patients must understand willing give write informed consent prior study procedure evaluation willing adhere study schedule requirement . 2 . Hb level : &gt; 6 gr/dl &lt; 10 gr/dl ; 3 . Age : &gt; 18 65 year ; 4 . Body Mass Index ≥20 ≤30 kg/m2 ; 5 . Documented 12lead ECG clinically significant abnormality , determine Investigator ; 6 . Female subject reproductive potential must negative serum pregnancy ( βHCG ) test screen negative urine pregnancy test Day 0 prior dose . Female subject must also nonlactating ; 7 . Adequate venous access receive intravenous infusion ; 8 . Frequency ER hospitalization &lt; 6x/yr SCD pain event document `` medical history '' . Exclusion : 1 . In medical opinion investigator , patient appropriate candidate ; 2 . Patient infect ; 3 . The patient Febrile ; 4 . Patient Acute chest syndrome document Sickle Cell Crisis ; 5 . Patient hemoglobin 10gr/dl 6 gm/dl 6 . If female , pregnant lactating ; 7 . History clinically significant disease , determine Investigator ; 8 . History allergy major allergic reaction consider clinically significant Investigator ; 9 . Physical examination 12lead ECG result ( ) consider clinically significant Investigator ; 10 . Received intending receive vaccination two week prior dose , anytime study participation ; 11 . Unable comply study attendance , protocol procedure study requirement ; 12 . Frequency ER hospitalization &gt; 6x/yr SCD pain event ; 13 . Patient Renal liver dysfunction ; 14 . Patient Severe pulmonary hypertension ( index &gt; 3 meter per sec base documented Echocardiograph ) ; 15 . Any history significant cardiac , renal , neurologic , metabolic , pulmonary , gastrointestinal , chronic hepatic disease disease judgment investigator would interfere study confound result ; 16 . Screening laboratory result indicate HIVpositivity , previously diagnose AIDS , AIDS relate complex , immunodeficiency ; 17 . Screening laboratory result indicate serologic positivity hepatitis C antibodies hepatitis B surface antigen , unless explain documented vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>SCD</keyword>
</DOC>